{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+dexamethasone&page=2",
    "query": {
      "intervention": "Oral dexamethasone",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 742,
    "total_pages": 75,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+dexamethasone&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+dexamethasone&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T10:47:37.102Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00366834",
      "title": "Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Vomiting",
        "Nausea",
        "Nausea and Vomiting, Chemotherapy-Induced"
      ],
      "interventions": [
        {
          "name": "Casopitant (GW679769) oral tablets",
          "type": "DRUG"
        },
        {
          "name": "Casopitant (GW679769) intravenous",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone intravenous",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron oral tablets",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1840,
      "start_date": "2006-07",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2012-09-10",
      "last_synced_at": "2026-09-30T10:47:37.102Z",
      "location_count": 86,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Fayetteville, Arkansas + 78 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00366834"
    },
    {
      "nct_id": "NCT04501614",
      "title": "A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)",
        "Ph+ Mixed Phenotype Acute Leukemia (MPAL)",
        "Philadelphia Chromosome-Like ALL (Ph-like ALL)"
      ],
      "interventions": [
        {
          "name": "Ponatinib",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy Agents",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 11,
      "start_date": "2021-02-24",
      "completion_date": "2024-07-19",
      "has_results": true,
      "last_update_posted_date": "2025-10-02",
      "last_synced_at": "2026-09-30T10:47:37.102Z",
      "location_count": 13,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Diego, California + 10 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04501614"
    },
    {
      "nct_id": "NCT01402284",
      "title": "Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 45,
      "start_date": "2011-07-21",
      "completion_date": "2020-09-24",
      "has_results": true,
      "last_update_posted_date": "2021-03-02",
      "last_synced_at": "2026-09-30T10:47:37.102Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01402284"
    },
    {
      "nct_id": "NCT01856062",
      "title": "Ovulation Induction With Clomiphene Citrate and Dexamethasone",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Infertility"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "San Antonio Military Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 140,
      "start_date": "2013-05",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2014-02-28",
      "last_synced_at": "2026-09-30T10:47:37.102Z",
      "location_count": 1,
      "location_summary": "Fort Sam Houston, Texas",
      "locations": [
        {
          "city": "Fort Sam Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01856062"
    },
    {
      "nct_id": "NCT04942067",
      "title": "APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Amyloidosis"
      ],
      "interventions": [
        {
          "name": "APG-2575+ Pd",
          "type": "DRUG"
        },
        {
          "name": "APG-2575 + DRd",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ascentage Pharma Group Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2021-12-23",
      "completion_date": "2024-12-01",
      "has_results": false,
      "last_update_posted_date": "2023-10-25",
      "last_synced_at": "2026-09-30T10:47:37.102Z",
      "location_count": 3,
      "location_summary": "Jacksonville, Florida • New York, New York • Cleveland, Ohio",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04942067"
    },
    {
      "nct_id": "NCT00024167",
      "title": "Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Estramustine phosphate sodium",
          "type": "DRUG"
        },
        {
          "name": "Ketoconazole",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Vinblastine",
          "type": "DRUG"
        },
        {
          "name": "Strontium chloride Sr 89",
          "type": "RADIATION"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 265,
      "start_date": "2002-04",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2016-03-22",
      "last_synced_at": "2026-09-30T10:47:37.102Z",
      "location_count": 40,
      "location_summary": "Gainesville, Georgia • Savannah, Georgia • Hines, Illinois + 23 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Georgia"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Hines",
          "state": "Illinois"
        },
        {
          "city": "Rockford",
          "state": "Illinois"
        },
        {
          "city": "Bettendorf",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00024167"
    },
    {
      "nct_id": "NCT00072514",
      "title": "Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Nasal Type Extranodal NK/T-cell Lymphoma",
        "Anaplastic Large Cell Lymphoma",
        "Angioimmunoblastic T-cell Lymphoma",
        "Cutaneous B-cell Non-Hodgkin Lymphoma",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Hepatosplenic T-cell Lymphoma",
        "Intraocular Lymphoma",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Noncutaneous Extranodal Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Grade III Lymphomatoid Granulomatosis",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Adult T-cell Leukemia/Lymphoma",
        "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Recurrent Small Lymphocytic Lymphoma",
        "Small Intestine Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Testicular Lymphoma",
        "Waldenstrom Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2003-08",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2017-06-29",
      "last_synced_at": "2026-09-30T10:47:37.102Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00072514"
    },
    {
      "nct_id": "NCT00890552",
      "title": "A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Leukemia",
        "Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2009-04",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2017-03-22",
      "last_synced_at": "2026-09-30T10:47:37.102Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00890552"
    },
    {
      "nct_id": "NCT05053659",
      "title": "Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed Non Hodgkin Lymphoma",
        "Refractory Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Loncastuximab tesirine",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Paolo Caimi, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2022-06-20",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-09-30T10:47:37.102Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05053659"
    },
    {
      "nct_id": "NCT06136624",
      "title": "Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "Opevesostat",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Fludrocortisone acetate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1310,
      "start_date": "2023-12-31",
      "completion_date": "2030-02-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-09-30T10:47:37.102Z",
      "location_count": 48,
      "location_summary": "Orange, California • Palo Alto, California • Riverside, California + 41 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Highlands Ranch",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06136624"
    }
  ]
}